MedTrace Logo

Duloxetine for the Treatment of Generalized Anxiety Disorder

NCT00803361 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2010-12-17

Study results available
· View outcomes & findings →

Summary

This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Duloxetine

60 to 120 mg, capsules, oral, once a day for 15 weeks

DRUG

Placebo

placebo capsules, oral, once a day for 15 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time(UTC/GMT -5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803361 on ClinicalTrials.gov